Regulus Therapeutics

Type: Company
Name: Regulus Therapeutics
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Regulus Therapeutics Downgraded to Sell at TheStreet (RGLS)

Regulus Therapeutics (NASDAQ:RGLS)The analysts wrote, "Regulus Therapeutics (RGLS) has been downgraded by TheStreet Ratings from hold to sell. The company’s weaknesses can be seen in multiple areas, such as its weak operating cash flow and feeble growth ... [Published American Banking News - Apr 15 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 12 reports

Global Multiple Sclerosis (MS) Therapeutics Market Report

PR NewswireDUBLIN April 11 2014DUBLIN April 11 2014 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/btp9ds/global_multiple) has announced the addition of the report to their offering.(Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... [Published PharmiWeb - Apr 11 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 1 reports

Regulus Presents Positive Preclinical Data on miR-21 and miR-221 Oncology Programs In Oral and Poster Presentations at AACR 2014 Annual Meeting

LA JOLLA, Calif., April 7, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that three abstracts will be presented ... [Published PR Newswire: Health - Apr 07 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 1 reports

Regulus to Present at the 13th Annual Needham Healthcare Conference

LA JOLLA, Calif., April 4, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Neil W. Gibson, Ph.D., Chief Scientific ... [Published PR Newswire: General Business - Apr 04 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 1 reports

Regulus Therapeutics Short Interest Down 20.3% in March (RGLS)

Regulus Therapeutics (NASDAQ:RGLS) was the target of a large decline in short interest in the month of January. As of March 14th, there was short interest totalling 1,460,571 shares, a decline of 20.3% from the February 28th total of 1,832,140 shares, ... [Published American Banking News - Apr 04 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

REGULUS THERAPEUTICS : Rosetta Genomics Assigned Patent

By Targeted News ServiceALEXANDRIA, Va. , March 31 -- Regulus Therapeutics , San Diego , and Rosetta Genomics , Rehovot, Israel , have been assigned a patent (8,680,067) developed by five co-inventors for "targeting microRNAs for the treatment of liver ... [Published 4 Traders - Apr 01 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

Regulus and Alport Syndrome Foundation Raise Awareness of Life-Threatening, Genetic Kidney Disease

LA JOLLA, Calif., March 25, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, and the Alport Syndrome Foundation ("ASF"), a non-profit ... [Published PR Newswire: General Business - Mar 25 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 1 reports

Regulus Therapeutics Given Consensus Recommendation of “Buy” by Brokerages (NASDAQ:RGLS)

Regulus Therapeutics (NASDAQ:RGLS) has earned an average recommendation of "Buy" from the eight analysts that are currently covering the company, StockRatingsNetwork.com reports. One research analyst has rated the stock with a hold rating and five have ... [Published American Banking News - Mar 24 2014]
First reported Mar 20 2014 - Updated Mar 20 2014 - 1 reports

NIRI San Diego Presents Shareholder Activisim and Social/Networking Event on March 25

-- The San Diego Chapter of the National Investor Relations Institute (NIRI) will host a panel discussion on strategies for responding to shareholder activism.The discussion will be held on Tuesday, March 25 , from 5 to 6:30 p.m. and will be immediately ... [Published ITbriefing - Mar 20 2014]
First reported Mar 14 2014 - Updated Mar 14 2014 - 1 reports

Commit To Purchase Regulus Therapeutics At $10, Earn 27.1% Annualized Using Options

Investors eyeing a purchase of Regulus Therapeutics Inc (Symbol: RGLS) shares, but tentative about paying the going market price of $10.44/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting ... [Published Nasdaq - Mar 14 2014]
First reported Mar 11 2014 - Updated Mar 12 2014 - 2 reports

Focus on Regulus' Pipeline - Analyst Blog

Investors in the pharma/biotech space look forward to pipeline updates from these companies. Their investment decisions are often based on such updates. Moreover, pharma/biotech companies invest significantly to develop their pipelines. Successful development ... [Published Benzinga.com - Mar 12 2014]
First reported Mar 07 2014 - Updated Mar 07 2014 - 1 reports

Regulus Therapeutics initiates dosing of RG-101 in Phase I study

Regulus Therapeutics, a biopharmaceutical company, has initiated dosing of RG-101, a sGalNAc-conjugated anti-miR targeting microRNA-122 (miR-122), in healthy subjects in the Phase I clinical study. Regulus Therapeutics' Phase I study is being conducted ... [Published Pharmaceutical Business Review - Mar 07 2014]

Quotes

The analysts wrote, "Regulus Therapeutics (RGLS) has been downgraded by TheStreet Ratings from hold to sell. The company’s weaknesses can be seen in multiple areas, such as its weak operating cash flow and feeble growth in its earnings per share."
...to a close strategic relationship for many years to come," said Laurence Reid, Ph D , Senior Vice President and Chief Business Officer of Alnylam. "This additional investment in Alnylam represents a continued endorsement of their commitment to our collaborative efforts as we work together to develop and commercialize RNAi therapeutics as genetic medicines."
...to advancing scientific research for orphan diseases such as Alport Syndrome," said Kleanthis G Xanthopoulos , Ph D , President and CEO of Regulus. "We are hopeful that our relationship with the Alport Syndrome Foundation will advance our understanding of the disease and believe that ASF will serve as an invaluable resource to us as we develop RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport Syndrome.  We are excited to initiate a natural history of disease study for RG-012 in the third quarter this year and expect to initiate a Phase I clinical study of RG-012 in the first half of 2015."
...dosed our first human subject, advancing Regulus into a clinical-stage company," said Neil W Gibson , Ph D , Chief Scientific Officer of Regulus. "We continue to be encouraged by the preclinical data seen to date and believe that RG-101 has the potential to be a best-in-class host factor agent, specifically due to its pan-genotypic properties, including demonstrated efficacy in the hard to treat HCV genotype 3, and the potential for a once monthly dosing regimen.  We look forward to reporting data from the Phase I clinical study of RG-101 by the end of this year."

More Content

All (53) | News (37) | Reports (0) | Blogs (12) | Audio/Video (0) | Fact Sheets (0) | Press Releases (4)
sort by: Date | Relevance
Alnylam to Webcast Presentation at 13th Annual ... [Published Pharmacy Choice - 5 hours ago]
Regulus Therapeutics Downgraded to Sell at TheS... [Published American Banking News - Apr 15 2014]
Analysts’ Downgrades for April, 15th (AUDC, FET... [Published American Banking News - Apr 15 2014]
Global MicroRNA Market Report [Published Sys-Con Italia - Apr 15 2014]
Global Multiple Sclerosis (MS) Therapeutics Mar... [Published PharmiWeb - Apr 11 2014]
Global Multiple Sclerosis (MS) Therapeutics Mar... [Published KSWO - Apr 11 2014]
Recently Released Market Study: Hepatitis C - P... [Published SBWire - Apr 11 2014]
Global Multiple Sclerosis (MS) Therapeutics Mar... [Published ADVFN UK - Apr 11 2014]
Global Multiple Sclerosis (MS) Therapeutics Mar... [Published KATV - Apr 11 2014]
Global Multiple Sclerosis (MS) Therapeutics Mar... [Published Rock Hill Herald - Apr 11 2014]
Global Multiple Sclerosis (MS) Therapeutics Mar... [Published Sacramento Bee - Apr 11 2014]
Global Multiple Sclerosis (MS) Therapeutics Mar... [Published TheStreet.com - Apr 11 2014]
Global Multiple Sclerosis (MS) Therapeutics Mar... [Published Individual.com - Apr 11 2014]
Global Multiple Sclerosis (MS) Therapeutics Mar... [Published Yahoo! Finance - Apr 11 2014]
Global Multiple Sclerosis (MS) Therapeutics Mar... [Published Digital Journal - Apr 11 2014]
Global Multiple Sclerosis (MS) Therapeutics Mar... [Published OSIX News - Apr 11 2014]
Global Multiple Sclerosis (MS) Therapeutics Mar... [Published TickerTech.com - Apr 11 2014]
Alnylam’s McSwiggen Patent Upheld in European O... [Published Business Wire - Apr 07 2014]
Regulus Presents Positive Preclinical Data on m... [Published PR Newswire: Health - Apr 07 2014]
Regulus to Present at the 13th Annual Needham H... [Published PR Newswire: General Business - Apr 04 2014]
Regulus Therapeutics Short Interest Down 20.3% ... [Published American Banking News - Apr 04 2014]
ALNYLAM PHARMACEUTICALS : to Webcast Presentati... [Published 4 Traders - Apr 02 2014]
REGULUS THERAPEUTICS : Rosetta Genomics Assigne... [Published 4 Traders - Apr 01 2014]
Genzyme Exercises its Right to Purchase Additio... [Published BusinessWeek - Mar 26 2014]
Regulus and Alport Syndrome Foundation Raise Aw... [Published Michigan Live - Mar 25 2014]
Regulus and Alport Syndrome Foundation Raise Aw... [Published PR Newswire: General Business - Mar 25 2014]
Regulus Therapeutics Given Consensus Recommenda... [Published American Banking News - Mar 24 2014]
NIRI San Diego Presents Shareholder Activisim a... [Published ITbriefing - Mar 20 2014]
Regulus Commences Dosing RG-101 in Healthy Volu... [Published FirstWord Pharma - Mar 19 2014]
Commit To Purchase Regulus Therapeutics At $10,... [Published Nasdaq - Mar 14 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Regulus Presents Positive Preclinical Data on m... [Published PR Newswire: Health - Apr 07 2014]
LA JOLLA, Calif., April 7, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that three abstracts will be presented ...
Regulus to Present at the 13th Annual Needham H... [Published PR Newswire: General Business - Apr 04 2014]
LA JOLLA, Calif., April 4, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Neil W. Gibson, Ph.D., Chief Scientific ...
Regulus and Alport Syndrome Foundation Raise Aw... [Published PR Newswire: General Business - Mar 25 2014]
LA JOLLA, Calif., March 25, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, and the Alport Syndrome Foundation ("ASF"), a non-profit ...
Regulus Commences Dosing RG-101 in Healthy Volu... [Published PR Newswire: Health - Mar 05 2014]
LA JOLLA, Calif., March 5, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has commenced dosing RG-101, ...
Regulus Provides Strategic Update and Reports F... [Published PR Newswire: Health - Feb 27 2014]
LA JOLLA, Calif., Feb. 27, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today provided an update on its corporate strategy ...
1 2 3

Press Releases

sort by: Date | Relevance
Regulus Renews Strategic Alliance with Sanofi t... [Published Financial Services - Feb 05 2014]
Regulus Announces Addition to NASDAQ Biotechnol... [Published Financial Services - Dec 23 2013]
Regulus Reports Third Quarter 2013 Financial Re... [Published Financial Services - Nov 13 2013]
Arcturus Therapeutics Appoints Zachary A. Zimme... [Published PR Newswire - Oct 28 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.